Latest news with #AnoulackChanthivong
Business Upturn
28-05-2025
- Business
- Business Upturn
New South Wales Minister for Industry and Trade Visits Novotech Seoul Office to Strengthen Clinical Trial Collaboration
Sydney, Australia: Novotech, a globally recognized full-service clinical research organization (CRO) and scientific advisory company trusted by biotech and small- to mid-sized pharmaceutical companies to guide drug development at every phase, was honored to welcome The Hon. Anoulack Chanthivong, New South Wales (NSW) Minister for Industry and Trade, to its Seoul office on May 19. The Minister's visit highlights a deepening collaboration between South Korea and Australia in the field of clinical research and highlights the strategic importance of cross-border partnerships in advancing global drug development. This press release features multimedia. View the full release here: Novotech, a globally recognized full-service clinical research organization (CRO) and scientific advisory company trusted by biotech and small- to mid-sized pharmaceutical companies to guide drug development at every phase, was honored to welcome The Hon. Anoulack Chanthivong, New South Wales (NSW) Minister for Industry and Trade, to its Seoul office on May 19. 'Novotech is a fantastic success story demonstrating the global value of NSW's strengths in life sciences and clinical trials,' said Minister Chanthivong. 'I was thrilled to learn about Novotech's growth in the Republic of Korea and the central role their business plays in bringing Korean biotech innovation to the world. Investment NSW looks forward to continuing to support Novotech as it generates export dollars for our state while helping people around the world tackle serious health issues.' Minister Chanthivong was joined by a delegation including: Brooke O'Rourke, Chief of Staff to Minister Chanthivong. Rebecca McPhee, Deputy Secretary of Investment NSW. David Lawson, NSW Trade & Investment Commissioner for Japan & Korea. Yoojin Kim, NSW Trade & Investment Director for Korea. The delegation engaged with Novotech leaders Dr. Yooni Kim, Hyun Kim, and Lilian Kim, who shared insights into Novotech's growth as a global clinical research organization and the expanding role of South Korea as a premier destination for clinical trials. 'We are honored that the Australian NSW Trade Minister and senior officials from NSW Investment have selected Novotech as a leading example of collaboration between Australia and South Korea,' said Dr. Yooni Kim, Managing Director – Asia-Pacific at Novotech. 'This visit reinforces the strong and growing partnership between the two countries in the clinical research and biopharmaceutical sector. As the largest Australian-founded global services company operating in South Korea, Novotech is committed to creating more success stories that demonstrate the value of this collaboration. I believe Novotech's strong partnership with the Australian NSW government and their NSW Investment can mutually benefit Korean biotech companies and the Australian clinical trial market.' The discussion reinforced Novotech's strong partnership with Australia, supported by a track record of successful clinical trials and a shared vision for future innovation. With increasing interest from Korean biotechs to conduct research in Australia, both parties explored opportunities to enhance bilateral cooperation and accelerate cross-border clinical development. Novotech, recently recognized as the Best CRO in Australia by IMAPAC's Asia-Pacific Biopharma Excellence Awards, continues to solidify its position as the region's leading clinical development partner. The company offers Korean biotech sponsors seamless access to Australia's world-class research infrastructure, regulatory expertise, and accelerated clinical pathways. Through its integrated full-service model, Novotech enables Korean biotechs to confidently expand early-phase programs into Australia, backed by deep regional knowledge and globally aligned operational standards. About Novotech Novotech is a globally recognized full-service clinical research organization (CRO) and scientific advisory company trusted by biotech and small- to mid-sized pharmaceutical companies to guide drug development at every phase. With a global footprint that includes 30+ offices across the Asia-Pacific region, North America, and Europe and partnerships with 5,000+ trial sites, Novotech provides clients an accelerated path to bring life-changing therapies to market by providing access to key clinical trial destinations and diverse patient populations. Through its client-centric service model, Novotech seamlessly integrates people, processes, and technologies to deliver customized solutions that accelerate the path to market for life-changing therapies. By adopting a true partnership approach, Novotech shares a steadfast commitment to client success, empowering innovation, and advancing healthcare worldwide. Recipient of numerous industry accolades, including the Frost & Sullivan CRO Company of the Year award for 19 consecutive years, Novotech is recognized for its excellence in clinical trial execution and innovation. Its deep therapeutic and regulatory expertise, combined with local market insights, ensures streamlined clinical trials, optimized data analytics, and accelerated patient recruitment strategies. Together with clients, Novotech transforms scientific advancements into therapies that improve global health outcomes, embodying a mission of driving innovation and delivering impactful results For more information or to speak to an expert team member visit View source version on Disclaimer: The above press release comes to you under an arrangement with Business Wire. Business Upturn takes no editorial responsibility for the same.
Business Wire
27-05-2025
- Business
- Business Wire
New South Wales Minister for Industry and Trade Visits Novotech Seoul Office to Strengthen Clinical Trial Collaboration
SYDNEY--(BUSINESS WIRE)--Novotech, a globally recognized full-service clinical research organization (CRO) and scientific advisory company trusted by biotech and small- to mid-sized pharmaceutical companies to guide drug development at every phase, was honored to welcome The Hon. Anoulack Chanthivong, New South Wales (NSW) Minister for Industry and Trade, to its Seoul office on May 19. The Minister's visit highlights a deepening collaboration between South Korea and Australia in the field of clinical research and highlights the strategic importance of cross-border partnerships in advancing global drug development. Novotech, a leading global CRO trusted by biotech and mid-sized pharma to guide drug development, was honored to welcome The Hon. Anoulack Chanthivong, New South Wales (NSW) Minister for Industry and Trade, to its Seoul office on May 19. Share 'Novotech is a fantastic success story demonstrating the global value of NSW's strengths in life sciences and clinical trials,' said Minister Chanthivong. 'I was thrilled to learn about Novotech's growth in the Republic of Korea and the central role their business plays in bringing Korean biotech innovation to the world. Investment NSW looks forward to continuing to support Novotech as it generates export dollars for our state while helping people around the world tackle serious health issues.' Minister Chanthivong was joined by a delegation including: Brooke O'Rourke, Chief of Staff to Minister Chanthivong. Rebecca McPhee, Deputy Secretary of Investment NSW. David Lawson, NSW Trade & Investment Commissioner for Japan & Korea. Yoojin Kim, NSW Trade & Investment Director for Korea. The delegation engaged with Novotech leaders Dr. Yooni Kim, Hyun Kim, and Lilian Kim, who shared insights into Novotech's growth as a global clinical research organization and the expanding role of South Korea as a premier destination for clinical trials. 'We are honored that the Australian NSW Trade Minister and senior officials from NSW Investment have selected Novotech as a leading example of collaboration between Australia and South Korea,' said Dr. Yooni Kim, Managing Director – Asia-Pacific at Novotech. 'This visit reinforces the strong and growing partnership between the two countries in the clinical research and biopharmaceutical sector. As the largest Australian-founded global services company operating in South Korea, Novotech is committed to creating more success stories that demonstrate the value of this collaboration. I believe Novotech's strong partnership with the Australian NSW government and their NSW Investment can mutually benefit Korean biotech companies and the Australian clinical trial market.' The discussion reinforced Novotech's strong partnership with Australia, supported by a track record of successful clinical trials and a shared vision for future innovation. With increasing interest from Korean biotechs to conduct research in Australia, both parties explored opportunities to enhance bilateral cooperation and accelerate cross-border clinical development. Novotech, recently recognized as the Best CRO in Australia by IMAPAC's Asia-Pacific Biopharma Excellence Awards, continues to solidify its position as the region's leading clinical development partner. The company offers Korean biotech sponsors seamless access to Australia's world-class research infrastructure, regulatory expertise, and accelerated clinical pathways. Through its integrated full-service model, Novotech enables Korean biotechs to confidently expand early-phase programs into Australia, backed by deep regional knowledge and globally aligned operational standards. About Novotech Novotech is a globally recognized full-service clinical research organization (CRO) and scientific advisory company trusted by biotech and small- to mid-sized pharmaceutical companies to guide drug development at every phase. With a global footprint that includes 30+ offices across the Asia-Pacific region, North America, and Europe and partnerships with 5,000+ trial sites, Novotech provides clients an accelerated path to bring life-changing therapies to market by providing access to key clinical trial destinations and diverse patient populations. Through its client-centric service model, Novotech seamlessly integrates people, processes, and technologies to deliver customized solutions that accelerate the path to market for life-changing therapies. By adopting a true partnership approach, Novotech shares a steadfast commitment to client success, empowering innovation, and advancing healthcare worldwide. Recipient of numerous industry accolades, including the Frost & Sullivan CRO Company of the Year award for 19 consecutive years, Novotech is recognized for its excellence in clinical trial execution and innovation. Its deep therapeutic and regulatory expertise, combined with local market insights, ensures streamlined clinical trials, optimized data analytics, and accelerated patient recruitment strategies. Together with clients, Novotech transforms scientific advancements into therapies that improve global health outcomes, embodying a mission of driving innovation and delivering impactful results
The Guardian
02-03-2025
- Politics
- The Guardian
Parklea correctional centre to return to public hands as NSW reverses ‘failed prison for profit model'
One of New South Wales's largest prisons will return to public hands as Labor continues to reverse what the union representing guards has dubbed 'the failed prison for profit model'. The Minns government announced on Sunday its contract with MTC Australia – a subsidiary of a controversial American private prison operator – to run Parklea correctional centre would end in October 2026. The Sydney prison is the second of three privately run prisons in the state to begin a transition back to public hands, with the 16-month transition for Junee correctional centre to return to public hands to be finalised in April. Guardian Australia understands the Minns government has no plan to return NSW's third and soon to be final privately-run prison – Clarence correctional centre – to state hands due to the cost of exiting the current contract. Sign up for Guardian Australia's breaking news email In 2020, the then Coalition government signed a 20-year contract with Serco, which operates the prison in Grafton. The state minister for corrections, Anoulack Chanthivong, said the move to transition Parklea and Junee was part of the Minns government's election promise to reverse the privatisation of public assets. 'Unlike private management, the Corrective Services NSW's operating model is not based on a profit motive, it's based on the objective to reduce reoffending following release from prison, which focuses on rehabilitation, education and safe reintegration into the community,' Chanthivong said. 'By bringing Junee and Parklea correctional centres back into public hands, we're delivering better value for NSW taxpayers and improving outcomes for workers, inmates and the community.' Early last year, two inmates at Parklea – which was privatised in 2009 – died in a suspected suicide within two months. This led the Greens' justice spokesperson, Sue Higginson, to say there could be more deaths at Parklea if there wasn't urgent reform. The union for prison staff, the Public Service Association (PSA), said the return of Junee and now Parklea to public hands showed NSW Labor was 'listening to our voice' that 'privatisation hurts everyone'. 'From the moment Parklea correctional centre was privatised in 2009, our union has campaigned for what is right: the return of the jail to the people of NSW and away from the failed prison for profit model that fails staff and taxpayers,' the PSA general secretary, Stewart Little, said. 'It's good news for the taxpayer, who will no longer be propping up outsourcing giants such as MTC that operate to benefit overseas shareholders rather than the people of NSW.' Sign up to Breaking News Australia Get the most important news as it breaks after newsletter promotion In 2023, when Labor announced it would de-privatise Junee correctional centre, a source with knowledge of the prison and not authorised to speak publicly said: 'The American model of prisons for profit – I don't think that works well in Australia.' They said that 'actively working towards rehabilitation' of prisoners was 'hard to do privately'. In December, Guardian Australia revealed the Albanese government would end a longstanding deal with Serco and pay $2.3bn to a local subsidiary of MTC, Secure Journeys, to run Australia's onshore immigration detention network. The NSW premier, Chris Minns, said the decision to de-privatise Parklea was a win for workers 'as we rebuild essential services for NSW'. 'Frontline staff who work at Parklea correctional centre today will have a job at Parklea – regardless of the changes,' Minns said. MTC Australia was contacted for comment.
